Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2006
Event: Non-reliance on previously issued financial statements and announcement of a restatement.
The Audit Committee determined that financial results for fiscal years 2003 and 2004, and the quarters ended March 31, June 30, and September 30, 2005, must be restated. This decision followed a routine SEC review of the Company's Form 10-K for 2004 and Form 10-Q for the quarter ended March 31, 2005. All related earnings releases for these periods, including the fourth quarter and full year 2005, should no longer be relied upon.
Key Financial Metrics and Restatement Impact
The restatement primarily concerns revenue recognition accounting regarding a $7,509,000 license and maintenance fee payment from Genentech under a June 2003 collaboration. The Company previously recognized $2,239,000 of this revenue between 2003 and Q3 2005 but has determined it should defer the entire amount indefinitely due to ongoing steering committee obligations. Additionally, $410,000 in license fees payable to university licensors should have been expensed immediately in June 2003 rather than amortized.
Cash Flow Impact: The restatement relates to amounts already collected and does not impact cash or cash flows from operations.
Impact on Net Loss (Unaudited):
| Period | Previously Reported Net Loss | Adjustment to Net Loss | Percent Variation |
|---|---|---|---|
| Year Ended Dec 31, 2004 | $(13,904,000) | $(1,145,000) | 8.2% |
| Year Ended Dec 31, 2003 | $(11,623,000) | $(1,057,000) | 9.1% |
| 9 Months Ended Sep 30, 2005 | $(13,419,000) | $(102,000) | 0.8% |
| Q3 2005 (Sep 30) | $(3,631,000) | $335,000 (Decrease in loss) | (9.2%) |
| Q2 2005 (Jun 30) | $(4,675,000) | $(176,000) | 3.8% |
| Q1 2005 (Mar 31) | $(5,113,000) | $(261,000) | 5.1% |
Balance Sheet Impact (Deferred Revenues):
- September 30, 2005: Increase of $2,239,000
- December 31, 2004: Increase of $408,000
- December 31, 2003: Decrease of $4,821,000
Material Changes and Accounting Corrections
The primary material change is the reversal of revenue recognition for the Genentech collaboration. The Company had previously estimated an eight-year recognition period based on product approval timelines. It now determines that steering committee obligations are indefinite, requiring the deferral of the $7,509,000 payment until obligations cease. Furthermore, the Company will correct immaterial errors previously aggregated in the Q3 2005 report by allocating them to the correct periods.
Outlook, Risks, and Management Commentary
Internal Controls: Management previously concluded that internal controls were effective as of December 31, 2004. Due to this restatement, management is reevaluating that conclusion. An evaluation for December 31, 2005, is also pending. Management acknowledges the possibility that one or more control deficiencies may constitute material weaknesses for both periods, which would preclude a conclusion of effective internal controls.
Audit Status: The restatement is not yet complete and is subject to audit or review by the Company's independent registered public accountants, PricewaterhouseCoopers LLP.
Future Revenue: The Company expects it will not record any revenue related to the Genentech payments for at least several years.
Investor Verification Checklist
- Verify the final audited restated financial statements once issued by PricewaterhouseCoopers LLP.
- Monitor the Company's upcoming filings for the formal conclusion on the effectiveness of internal controls over financial reporting for 2004 and 2005.
- Review the specific terms of the Genentech collaboration agreement to understand the duration of steering committee obligations.
- Confirm that the restatement does not impact the Company's current liquidity or cash position.